Text Size

MK0249 for the Treatment of Cognitive Impairment in Patients With Schizophrenia (0249-016)

This study has been completed.
Sponsor:
Information provided by:
Merck
ClinicalTrials.gov Identifier:
NCT00506077
First received: July 24, 2007
Last updated: February 10, 2011
Last verified: February 2011
History of Changes
Results First Received: October 13, 2010  
Study Type: Interventional
Study Design: Allocation: Randomized;   Endpoint Classification: Safety/Efficacy Study;   Intervention Model: Crossover Assignment;   Masking: Double Blind (Subject, Investigator);   Primary Purpose: Treatment
Condition: Paranoid Schizophrenia
Interventions: Drug: MK0249
Drug: Comparator: Placebo (unspecified)

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
First Patient Dosed: 11 February 2008; Last Patient Last Treatment: 08 October 2008. Six ex-U.S. study centers (3 Russia, 3 India).

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
At visit 1, patients were assessed using the protocol eligibility criteria. Eligible patients continued into an 8 day single-blind placebo washout/run-in period, and then were randomized at visit 3 to 1 of 2 cross-over treatment sequences.

Reporting Groups
  Description
MK0249 Then Placebo These subjects received MK0249 during Treatment Period 1 and Placebo during Treatment Period 2.
Placebo Then MK0249 These subjects received Placebo during Treatment Period 1 and MK0249 during Treatment Period 2.

Participant Flow for 3 periods

 Period 1:   Treatment Period 1
    MK0249 Then Placebo     Placebo Then MK0249  
STARTED     28     27  
COMPLETED     24     24  
NOT COMPLETED     4     3  
Adverse Event                 2                 1  
Lost to Follow-up                 0                 2  
Withdrawal by Subject                 2                 0  

Period 2:   Washout
    MK0249 Then Placebo     Placebo Then MK0249  
STARTED     24     24  
COMPLETED     24     24  
NOT COMPLETED     0     0  

Period 3:   Treatment Period 2
    MK0249 Then Placebo     Placebo Then MK0249  
STARTED     24     24  
COMPLETED     23     23  
NOT COMPLETED     1     1  
Adverse Event                 0                 1  
Withdrawal by Subject                 1                 0  



  Baseline Characteristics
  Hide Baseline Characteristics

Reporting Groups
  Description
MK0249 Then Placebo These subjects received MK0249 during Treatment Period 1 and Placebo during Treatment Period 2.
Placebo Then MK0249 These subjects received Placebo during Treatment Period 1 and MK0249 during Treatment Period 2.
Total Total of all reporting groups

Baseline Measures
    MK0249 Then Placebo     Placebo Then MK0249     Total  
Number of Participants  
[units: participants]
 		  28     27     55  
Age  
[units: years]
Mean ± Standard Deviation 		  30.7  ± 7.5     32.5  ± 8.4     31.6  ± 7.9  
Gender  
[units: participants]
 		     
Female     8     7     15  
Male     20     20     40  



  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Mean Change From Baseline at 4 Weeks of Treatment in Total Cognitive Score on the Brief Assessment of Cognition in Schizophrenia (BACS) Battery.   [ Time Frame: Baseline and 4 weeks of treatment ]
  Show Outcome Measure 1

2.  Secondary:   Mean Change From Baseline at 4 Weeks of Treatment in Attention/Processing Speed Composite Score   [ Time Frame: Baseline and 4 weeks of treatment ]
  Show Outcome Measure 2

3.  Secondary:   Mean Change From Baseline at 4 Weeks of Treatment in Episodic Memory Composite Score   [ Time Frame: Baseline and 4 weeks of treatment ]
  Show Outcome Measure 3

4.  Secondary:   Mean Change From Baseline at 4 Weeks of Treatment in Working Memory Composite Score   [ Time Frame: Baseline and 4 weeks of treatment ]
  Show Outcome Measure 4

5.  Other Pre-specified:   Pre-randomization Baseline: Total Cognitive Score on the Brief Assessment of Cognition in Schizophrenia (BACS) Battery.   [ Time Frame: Pre-randomization Baseline ]
  Show Outcome Measure 5

6.  Other Pre-specified:   Pre-randomization Baseline: Attention/Processing Speed Composite Score   [ Time Frame: Pre-randomization Baseline ]
  Show Outcome Measure 6

7.  Other Pre-specified:   Pre-randomization Baseline: Episodic Memory Composite Score   [ Time Frame: Pre-randomization Baseline ]
  Show Outcome Measure 7

8.  Other Pre-specified:   Pre-randomization Baseline: Working Memory Composite Score   [ Time Frame: Pre-randomization Baseline ]
  Show Outcome Measure 8


  Serious Adverse Events
  Show Serious Adverse Events


  Other Adverse Events
  Hide Other Adverse Events

Time Frame Patients were assessed for adverse events (AEs) from visit 2 (V2) (Day -7): Neuropsych Testing through visit 11 (V11) (Day 77): 2-week Follow-Up.
Additional Description Abnormal Involuntary Movement Scale (AIMS), Simpson-Angus Scale (SAS), and Barnes Akathisia Rating Scale (BARS) were administered at visit 1 (V1), visit 6 (V6), and visit 10 (V10) to help assess for certain AEs.

Frequency Threshold
Threshold above which other adverse events are reported   2%  

Reporting Groups
  Description
MK0249 10 mg per day of MK-0249 were taken orally for Treatment Period 1 or Treatment Period 2 (depending on the sequence). At any time after 3 days of double-blind treatment if patients who were unable to tolerate 10 mg per day, they were allowed to titrate down to 7 mg per day and remained on 7 mg per day for the remainder of the treatment period.
Placebo 10 mg per day of matching placebo were taken orally for Treatment Period 1 or Treatment Period 2 (depending on the sequence). At any time after 3 days of double-blind treatment if patients who were unable to tolerate 10 mg per day, they were allowed to titrate down to 7 mg per day and remained on 7 mg per day for the remainder of the treatment period.

Other Adverse Events
    MK0249     Placebo  
Total, other (not including serious) adverse events      
# participants affected / at risk     20/52     15/51  
Gastrointestinal disorders      
nausea * 1    
# participants affected / at risk     4/52 (7.69%)     3/51 (5.88%)  
General disorders      
irritability * 1    
# participants affected / at risk     0/52 (0.00%)     3/51 (5.88%)  
Infections and infestations      
nasopharyngitis * 1    
# participants affected / at risk     1/52 (1.92%)     2/51 (3.92%)  
Investigations      
alanine aminotransferase increased * 1    
# participants affected / at risk     1/52 (1.92%)     2/48 (4.17%)  
aspartate aminotransferase increased * 1    
# participants affected / at risk     0/52 (0.00%)     2/48 (4.17%)  
blood creatine phosphokinase increased * 1    
# participants affected / at risk     1/52 (1.92%)     1/48 (2.08%)  
blood creatinine increased * 1    
# participants affected / at risk     0/52 (0.00%)     1/48 (2.08%)  
blood urea increased * 1    
# participants affected / at risk     0/52 (0.00%)     1/48 (2.08%)  
eosinophil count increased * 1    
# participants affected / at risk     0/52 (0.00%)     1/48 (2.08%)  
lymphocyte count increased * 1    
# participants affected / at risk     0/52 (0.00%)     1/48 (2.08%)  
neutrophil count decreased * 1    
# participants affected / at risk     0/52 (0.00%)     1/48 (2.08%)  
platelet count increased * 1    
# participants affected / at risk     1/52 (1.92%)     1/48 (2.08%)  
white blood cell count increased * 1    
# participants affected / at risk     1/52 (1.92%)     2/48 (4.17%)  
Musculoskeletal and connective tissue disorders      
pain in extremity * 1    
# participants affected / at risk     1/52 (1.92%)     2/51 (3.92%)  
Nervous system disorders      
headache * 1    
# participants affected / at risk     6/52 (11.54%)     2/51 (3.92%)  
Psychiatric disorders      
anxiety * 1    
# participants affected / at risk     5/52 (9.62%)     2/51 (3.92%)  
insomnia * 1    
# participants affected / at risk     7/52 (13.46%)     4/51 (7.84%)  
middle insomnia * 1    
# participants affected / at risk     2/52 (3.85%)     0/51 (0.00%)  
* Events were collected by non-systematic assessment
1 Term from vocabulary, MedDRA (11.0)



  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
The agreement is:
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.


Limitations and Caveats
Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.  


Results Point of Contact:  
Name/Title: Vice President of Late Stage Development
Organization: Merck Sharp & Dohme Corp
phone: 1-800-672-6372
e-mail: ClinicalTrialsDisclosure@spcorp.com


No publications provided by Merck

Publications automatically indexed to this study:


Responsible Party: Executive Vice President, Clinical and Quantitative Sciences, Merck & Co., Inc.
ClinicalTrials.gov Identifier: NCT00506077     History of Changes
Other Study ID Numbers: MK-0249-016, 2007_522
Study First Received: July 24, 2007
Results First Received: October 13, 2010
Last Updated: February 10, 2011
Health Authority: Russia: Pharmacological Committee, Ministry of Health